Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Victory and defeat at Heraclea - treating hepatitis C infection following liver transplantation with telaprevir and boceprevir.

Charlton M, Dick T.

J Hepatol. 2014 Jan;60(1):6-8. doi: 10.1016/j.jhep.2013.10.006. Epub 2013 Oct 12. No abstract available.

2.

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.

Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC.

J Hepatol. 2014 Jan;60(1):78-86. doi: 10.1016/j.jhep.2013.08.018. Epub 2013 Aug 29.

PMID:
23994384
3.

Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation.

Ikegami T, Yoshizumi T, Shirabe K, Maehara Y.

J Hepatol. 2014 Apr;60(4):894-6. doi: 10.1016/j.jhep.2013.10.037. Epub 2013 Dec 4. No abstract available.

4.

Reply to: "Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation".

Coilly A, Sebagh M, Duclos-Vallée JC.

J Hepatol. 2014 Apr;60(4):896-7. doi: 10.1016/j.jhep.2013.11.032. Epub 2013 Dec 4. No abstract available.

5.

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J.

J Viral Hepat. 2012 May;19 Suppl 2:1-26. doi: 10.1111/j.1365-2893.2012.01590.x. Review.

PMID:
22404758
6.

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

Swiss Association for the Study of the Liver.

Swiss Med Wkly. 2012 Feb 24;142:w13516. doi: 10.4414/smw.2012.13516. Review.

7.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
8.

Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.

Chevaliez S.

Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S46-51. doi: 10.1016/S2210-7401(11)70007-9.

PMID:
22248694
9.

Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).

Italian Association for the Study of the Liver (AISF), Coco B, Caraceni P, Aghemo A, Bitetto D, Bruno R, Ciancio A, Marzioni M, Petta S, Rendina M, Valenti L; Review Board:.

Dig Liver Dis. 2014 Jan;46(1):18-24. doi: 10.1016/j.dld.2013.08.243. Epub 2013 Oct 9. Review.

10.

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA.

J Hepatol. 2013 Jul;59(1):31-7. doi: 10.1016/j.jhep.2013.02.018. Epub 2013 Feb 27.

PMID:
23454058
11.

A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.

Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N.

Ann Hepatol. 2012 Mar-Apr;11(2):179-85. Review.

12.

Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.

Saxena V, Terrault N.

Curr Opin Organ Transplant. 2012 Jun;17(3):216-24. doi: 10.1097/MOT.0b013e3283534d64. Review.

PMID:
22476221
13.

[Telaprevir in treatment-naïve patients with HCV monoinfection].

Cabezas J, Crespo J, Selmo J, Luis Calleja J.

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:7-13. doi: 10.1016/S0213-005X(13)70118-6. Review. Spanish.

PMID:
24063897
14.

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.

Asselah T.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):455-62. doi: 10.1016/j.bpg.2012.09.003.

PMID:
23199504
15.

Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.

Smith LS, Nelson M, Naik S, Woten J.

Ann Pharmacother. 2011 May;45(5):639-48. doi: 10.1345/aph.1P430. Epub 2011 May 10. Review.

PMID:
21558488
16.

Telaprevir and boceprevir: a potential role for therapeutic drug monitoring.

Dolton MJ, Ray JE, McLachlan AJ.

Ther Drug Monit. 2013 Jun;35(3):414-5. doi: 10.1097/FTD.0b013e318285e87c. No abstract available.

PMID:
23670484
17.

Antiviral agents and hepatitis C.

Archer-Festa M, Nilsen-Kupsch S.

N Y State Dent J. 2012 Jun-Jul;78(4):42-5.

PMID:
23252194
18.

Telaprevir: an oral protease inhibitor for hepatitis C virus infection.

Kim JJ, Culley CM, Mohammad RA.

Am J Health Syst Pharm. 2012 Jan 1;69(1):19-33. doi: 10.2146/ajhp110123. Review.

PMID:
22180548
19.

[Direct antiviral treatment strategies in chronic hepatitis C].

Neumann-Haefelin C, Blum HE, Thimme R.

Dtsch Med Wochenschr. 2012 Jun;137(25-26):1360-5. doi: 10.1055/s-0032-1305064. Epub 2012 May 31. Review. German.

PMID:
22653493
20.

Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.

Hazuda DJ, Burroughs M, Howe AY, Wahl J, Venkatraman S.

Ann N Y Acad Sci. 2013 Jul;1291:69-76. doi: 10.1111/nyas.12218. Review.

PMID:
23859802

Supplemental Content

Support Center